

Sartorius Stedim Biotech S.A. - 13781 Aubagne France

ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT

Aubagne, France | January 2, 2020

Under the liquidity contract concluded between Sartorius Stedim Biotech S.A. and the stockbroker Gilbert Dupont, the following assets appeared on the liquidity account at December 31, 2019:

- Number of shares: 3,225
- Liquidity account cash balance: € 370,692.66

For information, the following assets appeared on the half-year report of the liquidity contract of June 28, 2019:

- Number of shares: 2,519
- Liquidity account cash balance: € 468,433.16

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2018, the company earned sales revenue of €1,212.2 million and currently employs more than 6,000 people.

Contact

Ben Orzelek
Investor Relations
+49(0)551.308.1668
ben.orzelek@sartorius.com

Sartorius Stedim Biotech SA

Z.I. Les Paluds
Avenue de Jouques, CS 91051
13781 Aubagne Cedex, France
Phone: +33.(0)4.42.84.56.00
Fax: +33.(0)4.42.84.56.19
www.sartorius-stedim.com